The paper reviews the first clinical follistatin gene therapy trial using the FS344 isoform in Becker muscular dystrophy. Six ambulatory BMD patients received dose-ascending AAV-delivered FS344 to build muscle mass. In each cohort of three subjects, two patients improved in the distance walked on the six-minute walk test.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.